• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Life Sciences Investor Forum Agenda Announced for March 13th

    3/12/25 1:12:37 PM ET
    $CGTX
    $COCP
    $FBLG
    $PDSB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CGTX alert in real time by email

    NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum March 13th. This event is co-hosted by Zacks Small Cap Research.

    Individual investors, institutional investors, advisors, and analysts are invited to attend.

    REGISTER NOW AT:   https://bit.ly/4hnure6

    It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management.

    "We look forward to bringing together innovators from the life sciences sector," said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. "This Virtual Investor Conference co-hosted by Zack's Small Cap Research, will provide an efficient platform for these companies to seamlessly engage and broaden their investor base." 

    March 13th

    Eastern

    Time (ET)
    PresentationTicker(s)
    9:30 AM ETCognition Therapeutics, Inc.(NASDAQ:CGTX)
    10:00 AM ETBiophytis SA(OTC:BPTSY, FP: ALBPS))
    10:30 AM ETAvicanna Inc.(OTCQX:AVCNF, TSX:AVCN)
    11:00 AM ETPsy Therapeutics, Inc.Private
    11:30 AM ETCocrystal Pharma, Inc.(NASDAQ:COCP)
    12:00 PM ETNervGen Pharma Corp.(OTCQB:NGENF, TSXV:NGEN)
    12:30 PM ETFibroBiologics, Inc.(NASDAQ:FBLG)
    1:00 PM ETTelescope Innovations Corp.(OTCQB:TELIF, CSE:TELI)
    1:30 PM ETRafarma Pharmaceuticals, Inc.(OTC:RAFA)
    2:00 PM ETIzotropic Corporation(OTCQB:IZOZF, CSE:IZO)
    2:30 PM ETPDS Biotechnology Corporation(NASDAQ:PDSB)
    3:00 PM ETLadRX Corporation(OTCQB:LADX)
    3:30 PM ETTonix Pharmaceuticals Holding Corp.(NASDAQ:TNXP)
    4:00 PM ETHemostemix, Inc.(OTCQB:HMTXF, TSXV:HEM)



    To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.

    About Virtual Investor Conferences®

    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

    Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

    Media Contact: 

    OTC Markets Group Inc. +1 (212) 896-4428, [email protected]

    Virtual Investor Conferences Contact:

    John M. Viglotti

    SVP Corporate Services, Investor Access

    OTC Markets Group

    (212) 220-2221

    [email protected]



    Primary Logo

    Get the next $CGTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CGTX
    $COCP
    $FBLG
    $PDSB

    CompanyDatePrice TargetRatingAnalyst
    Cognition Therapeutics Inc.
    $CGTX
    12/19/2024$1.00 → $1.50Neutral → Buy
    B. Riley Securities
    FibroBiologics Inc.
    $FBLG
    12/12/2024$12.00Buy
    Rodman & Renshaw
    FibroBiologics Inc.
    $FBLG
    10/30/2024$12.00Buy
    H.C. Wainwright
    FibroBiologics Inc.
    $FBLG
    9/24/2024$12.00Buy
    Maxim Group
    Cognition Therapeutics Inc.
    $CGTX
    7/30/2024Overweight → Neutral
    Cantor Fitzgerald
    PDS Biotechnology Corporation
    $PDSB
    11/1/2022$10.00Buy
    B. Riley Securities
    Tonix Pharmaceuticals Holding Corp.
    $TNXP
    4/18/2022Outperform
    Noble Capital Markets
    Cognition Therapeutics Inc.
    $CGTX
    11/3/2021$27.00Buy
    B. Riley Securities
    More analyst ratings

    $CGTX
    $COCP
    $FBLG
    $PDSB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      PRINCETON, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that on May 5, 2025, PDS Biotech granted a nonstatutory stock option to purchase 5,000 shares of common stock to an employee in its clinical department as a material inducement to such employee's employment and in accordance with Nasdaq Listing Rule 5635(c)(4) and PDS Biotech's 2019 Inducement Plan, as amended, which was adopted on June 17, 2019, and provides for the granting of equity awards to new employees of PDS Biotech. The stock option

      5/9/25 4:05:00 PM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health

      PURCHASE, N.Y., May 09, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc.  (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical data this week at the Association for Research in Vision and Ophthalmology (ARVO) showing the potential for zervimesine (CT1812) to protect retinal pigment epithelial (RPE) cells from damage in dry age-related macular degeneration (dry AMD). "Dry AMD is driven by a number of factors that contribute to the death of retinal cells, leading to irreversible vision loss," stated Mary Hamby, PhD, vice president of research. "Preclinical research presented at ARVO supports our understanding of zervime

      5/9/25 7:30:00 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting

      PRINCETON, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and infectious diseases, today provided updates on preclinical immune response data with a novel, investigational Infectimune® based flu vaccine that were featured at the American Association of Immunologists' IMMUNOLOGY2025™ Annual Meeting, which took place May 3-7, 2025, in Honolulu, Hawaii. As previously announced, on Sunday, May 4, 2025, Andrea Sant, Ph.D., Professor of Microbiology and Immunology at the University of Rochester Medical Center, presented

      5/8/25 8:00:00 AM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CGTX
    $COCP
    $FBLG
    $PDSB
    SEC Filings

    See more
    • SEC Form 8-K filed by Tonix Pharmaceuticals Holding Corp.

      8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

      5/8/25 5:16:06 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PDS Biotechnology Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - PDS Biotechnology Corp (0001472091) (Filer)

      5/8/25 8:05:20 AM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cognition Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)

      5/8/25 7:35:46 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGTX
    $COCP
    $FBLG
    $PDSB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Doyle John Brendan covered exercise/tax liability with 9,692 shares, decreasing direct ownership by 2% to 404,710 units (SEC Form 4)

      4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

      5/2/25 5:53:52 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CHIEF SCIENTIFIC OFFICER Khoja Hamid

      4 - FibroBiologics, Inc. (0001958777) (Issuer)

      3/28/25 4:10:10 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by General Counsel Garcia Ruben A

      4 - FibroBiologics, Inc. (0001958777) (Issuer)

      3/28/25 4:10:13 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CGTX
    $COCP
    $FBLG
    $PDSB
    Leadership Updates

    Live Leadership Updates

    See more

    $CGTX
    $COCP
    $FBLG
    $PDSB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

      August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Company expects to have sufficient cash to fund planned operations beyond the FDA PDUFA goal date and anticipated fourth quarter 2025 launch of TNX-102 SL for fibromyalgia; $98.8 million in cash as of December 31, 2024 Announced positive topline results from Phase 1 study of TNX-1500, a next generation anti-CD40L mAb candidate for prevention of kidney transplant rejection and treatment of autoimmune diseases Received government grant for potential mpox vaccine, TNX-801, which has demonst

      3/18/25 4:30:00 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Gary Ainsworth as Vice President of Market Access

      Mr. Ainsworth brings over two decades of industry and market access experience to Tonix U.S. Food and Drug Administration (FDA) recently assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for U.S. marketing authorization of TNX-102 SL for the management of fibromyalgia CHATHAM, N.J., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the appointment of Gary Ainsworth as Vice President, Market Access, effective immediately. Mr. Ainsworth is an accomplished executive with leadershi

      1/8/25 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Announces Expansion of Leadership Team with Two Strategic Hires

      Tonix appoints two executives with decades of experience successfully launching and commercializing new CNS products Bradley Raudabaugh, MBA, joins as Vice President, Marketing, bringing over 25 years of marketing, sales and product planning experience to Tonix Errol Gould, Ph.D., joins Tonix as Vice President, Medical Affairs, with over 25 years of experience in R&D and medical affairs across a wide range of therapeutic areas, including fibromyalgia New Drug Application (NDA) for TNX-102 SL for the management of fibromyalgia submitted to FDA in October 2024; NDA acceptance expected December 2024; Fast Track designation previously granted by FDA; FDA decision on approval expected 2025 If

      12/3/24 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

      SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

      11/14/24 4:42:22 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

      SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

      11/14/24 4:40:17 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

      SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

      10/16/24 9:01:20 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CGTX
    $COCP
    $FBLG
    $PDSB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Freitag Gregory Gene bought $25,000 worth of shares (15,060 units at $1.66), increasing direct ownership by 33% to 61,213 units (SEC Form 4)

      4 - PDS Biotechnology Corp (0001472091) (Issuer)

      3/3/25 4:45:42 PM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Glover Stephen C. bought $25,001 worth of shares (15,061 units at $1.66), increasing direct ownership by 24% to 78,851 units (SEC Form 4)

      4 - PDS Biotechnology Corp (0001472091) (Issuer)

      3/3/25 4:45:20 PM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO & President Ricciardi Lisa covered exercise/tax liability with 28,960 shares, was granted 631,300 shares and bought $30,001 worth of shares (38,851 units at $0.77), increasing direct ownership by 207% to 893,685 units (SEC Form 4)

      4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

      2/4/25 4:11:53 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGTX
    $COCP
    $FBLG
    $PDSB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cognition Therapeutics upgraded by B. Riley Securities with a new price target

      B. Riley Securities upgraded Cognition Therapeutics from Neutral to Buy and set a new price target of $1.50 from $1.00 previously

      12/19/24 7:33:00 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rodman & Renshaw initiated coverage on FibroBiologics with a new price target

      Rodman & Renshaw initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00

      12/12/24 8:54:24 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on FibroBiologics with a new price target

      H.C. Wainwright initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00

      10/30/24 6:37:36 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CGTX
    $COCP
    $FBLG
    $PDSB
    Financials

    Live finance-specific insights

    See more
    • PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results

      PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call to report financial results for the quarter ended March 31, 2025, and provide a clinical programs update on Wednesday, May 14, 2025 at 8:00 a.m. Eastern Time. Conference Call Details Date: May 14, 2025Time: 8:00 a.m. Eastern TimeDial-in: 1-877-704-4453 (Domestic) or 1-201-389-0920 (International) Webcast Registration: Click HereCall MeTM Registration: Click Here (Available 15 minutes prior to ca

      5/7/25 8:00:00 AM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update

      - End-of-Phase 2 meeting with FDA requested for Alzheimer's disease - - Phase 2 results in dementia with Lewy bodies accepted for oral presentation at AAIC - - Two posters at ARVO describe zervimesine's role supporting retinal cell health - PURCHASE, N.Y., May 07, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. "During our first quarter of 2025 and in recent weeks, we continued to advance our Alzheimer's disease and dementia with Lewy bodies (DLB

      5/7/25 7:30:15 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

      BOTHELL, Wash., March 31, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") reports financial results for the 12 months ended December 31, 2024, and provides updates on its antiviral product pipeline, upcoming milestones and business activities. "Our novel, potent antiviral compounds for norovirus, influenza and coronavirus address critical gaps in global health where effective treatments or vaccines are currently lacking," said Sam Lee, Ph.D., President and co-CEO of Cocrystal. "We plan to initiate a norovirus human challenge study in the U.S. later this year to evaluate our pan-viral protease inhibitor CDI-988 for the potential treatment and pr

      3/31/25 8:00:00 AM ET
      $COCP
      Biotechnology: Pharmaceutical Preparations
      Health Care